Interventional Cardiology, Dartmouth-Hitchcock Medical Center, Associate Professor of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756 USA.
J Invasive Cardiol. 2021 Aug;33(8):E640-E646. doi: 10.25270/jic/20.00670. Epub 2021 Jul 16.
The purpose of this analysis was to examine the association of iso-osmolar contrast media (IOCM) vs low-osmolar contrast media (LOCM) with major adverse renal or cardiovascular events (MARCE) in patients at high risk of acute kidney injury (AKI), undergoing endovascular abdominal aortic aneurysm repair (EVAR).
Patients at high risk of AKI (defined as age ≥75 years, or one or more of the following comorbidities: diabetes, anemia, chronic kidney disease (CKD stages 1-4) or congestive heart failure), undergoing EVAR from September 2012 to June 2018 were identified using the Premier Hospital Database. We compared the primary endpoint of MARCE (composite of AKI, AKI requiring dialysis, acute myocardial infarction [AMI], stroke/transient ischemic attack [TIA], and death) with IOCM vs LOCM via adjusted multivariable regression analyses.
Among 15,777 high-risk patients undergoing EVAR, the occurrence of in-hospital MARCE was 6.8%, including renal events (4.5%), AMI (0.8%), stroke/TIA (0.4%), and death (1.9%), IOCM was used in 7360 patients (47%). Multivariable modeling found IOCM was associated with 1.8% (95% confidence interval [CI], 0.4-3.3; P=.01) lower absolute risk for MARCE (23.9% relative risk reduction; 95% CI, 5.2%-44.2%).
Use of IOCM vs LOCM in patients at high risk of AKI undergoing EVAR procedures was associated with a lower risk of MARCE. As prevention of AKI or cardiovascular events after EVAR procedures may lead to reduced morbidity and mortality, this finding may have important clinical implications and should be confirmed through randomized controlled clinical studies.
本分析旨在研究等渗对比剂(IOCM)与低渗对比剂(LOCM)与高急性肾损伤(AKI)风险患者血管内腹主动脉瘤修复(EVAR)后主要不良肾脏或心血管事件(MARCE)的相关性。
使用 Premier 医院数据库,确定 2012 年 9 月至 2018 年 6 月期间年龄≥75 岁或有以下一种或多种合并症的高 AKI 风险(定义为)的患者:糖尿病、贫血、慢性肾脏病(CKD 1-4 期)或充血性心力衰竭)进行 EVAR。通过调整后的多变量回归分析,我们比较了 IOCM 与 LOCM 的主要终点 MARCE(AKI、需要透析的 AKI、急性心肌梗死 [AMI]、中风/短暂性脑缺血发作 [TIA]和死亡的复合)。
在 15777 例接受 EVAR 的高危患者中,住院期间 MARCE 的发生率为 6.8%,包括肾脏事件(4.5%)、AMI(0.8%)、中风/TIA(0.4%)和死亡(1.9%),IOCM 用于 7360 例患者(47%)。多变量模型发现 IOCM 与 MARCE 的绝对风险降低 1.8%(95%置信区间 [CI],0.4-3.3;P=.01)相关(相对风险降低 23.9%;95%CI,5.2%-44.2%)。
在接受 EVAR 手术的高 AKI 风险患者中,IOCM 与 LOCM 的使用与 MARCE 的风险降低相关。由于预防 EVAR 术后 AKI 或心血管事件可能会降低发病率和死亡率,因此这一发现可能具有重要的临床意义,并应通过随机对照临床试验得到证实。